Abstract
Mesenchymal stem/stromal cells (MSCs) can be used as a therapeutic agent
in regenerative medicine, owing to their unique self-renewal, multi-lineage
differentiation, and immunoregulation properties. The manufacturing of authorized
MSC products should depend on good manufacturing practices (GMP), Good
Laboratory Practice (GLP), and Good Clinical Practice (GCP). Until now, many
biotech companies have invested in developing the clinical application of MSC product
all over the world. Meanwhile, the application of MSC products for human use must
comply with regulations and guidance for a biotech company. In this chapter, we
discuss the process and development of MSC products from production-manufacturing
to commercialization.
Related Journals
Current Dentistry
Current Psychopharmacology
Recent Advances in Anti-Infective Drug Discovery
Anti-Infective Agents
Adolescent Psychiatry
Current Aging Science
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current HIV Research
Current Neurovascular Research
Current Respiratory Medicine Reviews
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents